Hangzhou ThinHeal Pharma-Tech Co., Ltd.: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Hangzhou ThinHeal Pharma-Tech Co., Ltd.?
Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by Hangzhou ThinHeal Pharma-Tech Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, on May 1, 2025. 2 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Qiantang District, Hangzhou
- FEI numbers on the lines
- 3033182388
- Refused lines
- 2
- Lines with an Import Alert 66-80 API or powder code
- 2
- Drugs named in the product codes
- Semaglutide, Tirzepatide
- Refusal dates
- May 1, 2025
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Hangzhou ThinHeal Pharma-Tech Co., Ltd. is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| May 1, 2025 | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2501606-4/12/1 |
| May 1, 2025 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2501606-4/12/2 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 2 |
| FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 2 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
2 lines from FDA files read Nov 15, 2026.